ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,026Medicare Part D Prescriptions Filled, Including Refills

Rank: 56 out of 151

$412K Total Retail Price of All Prescriptions

Rank: 66 out of 151

412 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
53% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 412 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

11% of this provider’s 412 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 7,943 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$46 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
OMEPRAZOLE 440 392 1 4
AMLODIPINE BESYLATE 360 339 2 3
LEVOTHYROXINE SODIUM 348 324 3 2
LISINOPRIL 305 285 4 5
WARFARIN SODIUM 283 276 5 9
SIMVASTATIN 268 231 6 1
FUROSEMIDE 266 234 7 6
METOPROLOL TARTRATE 212 191 8 7
HYDROCODONE-ACETAMINOPHEN 202 183 S3 9 10
LOSARTAN POTASSIUM 175 175 10 12
METOPROLOL SUCCINATE 136 132 11 21
LOVASTATIN 134 119 12 31
CITALOPRAM HBR 128 124 13 18
METFORMIN HCL 123 107 14 8
HYDROCHLOROTHIAZIDE 121 119 15 13
GABAPENTIN 109 70 16 14
POTASSIUM CHLORIDE 108 104 17 19
POLYETHYLENE GLYCOL 3350 102 91 18 78
CARVEDILOL 101 83 19 22
CYMBALTA 100 84 20 62
ATENOLOL 97 88 21 11
ZOLPIDEM TARTRATE 83 70 22 17
NYSTATIN 83 81 22 137
LORAZEPAM 80 80 24 94
ENALAPRIL MALEATE 74 63 25 38
PREDNISONE 73 42 26 45
CIPROFLOXACIN HCL 70 68 27 51
TAMSULOSIN HCL 67 66 28 30
NITROFURANTOIN MONO-MACRO 66 64 29 193
DIGOXIN 64 57 30 39
NAMENDA 62 62 31 20
CLONIDINE HCL 61 59 32 52
SPIRIVA 61 61 32 90
SPIRONOLACTONE 59 56 34 72
ESCITALOPRAM OXALATE 59 59 34 40
DONEPEZIL HCL 58 58 36 15
FENOFIBRATE 57 40 37 61
FAMOTIDINE 55 51 38 64
TRAMADOL HCL 55 47 38 24
LANTUS 54 22 40 47
VENTOLIN HFA 53 52 41 114
ISOSORBIDE MONONITRATE ER 52 52 42 55
METHYLPREDNISOLONE 51 44 43 91
DIVALPROEX SODIUM 51 25 43 79
LIDODERM 51 51 43 65
SERTRALINE HCL 50 38 46 25
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 18, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.